Cargando…

Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis

INTRODUCTION: Herpes zoster, which can have a major impact on quality of life, results from reactivation of a latent varicella zoster virus (VZV) infection. We hypothesized that giant cell arteritis (GCA) patients are at increased risk of herpes zoster because of treatment with high-dose glucocortic...

Descripción completa

Detalles Bibliográficos
Autores principales: Rondaan, Christien, van der Geest, Kornelis S. M., Eelsing, Elisabeth, Boots, Annemieke M. H., Bos, Nicolaas A., Westra, Johanna, Brouwer, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661055/
https://www.ncbi.nlm.nih.gov/pubmed/29118757
http://dx.doi.org/10.3389/fimmu.2017.01377
_version_ 1783274407123222528
author Rondaan, Christien
van der Geest, Kornelis S. M.
Eelsing, Elisabeth
Boots, Annemieke M. H.
Bos, Nicolaas A.
Westra, Johanna
Brouwer, Elisabeth
author_facet Rondaan, Christien
van der Geest, Kornelis S. M.
Eelsing, Elisabeth
Boots, Annemieke M. H.
Bos, Nicolaas A.
Westra, Johanna
Brouwer, Elisabeth
author_sort Rondaan, Christien
collection PubMed
description INTRODUCTION: Herpes zoster, which can have a major impact on quality of life, results from reactivation of a latent varicella zoster virus (VZV) infection. We hypothesized that giant cell arteritis (GCA) patients are at increased risk of herpes zoster because of treatment with high-dose glucocorticoids and advanced age. Aim of the study, therefore, was to determine cell-mediated and humoral immunity to VZV in patients with GCA, patients with closely related disease polymyalgia rheumatica (PMR; treated with lower doses of glucocorticoids) and healthy controls (HCs). METHODS: Cell-mediated immunity to VZV was determined by performing interferon-γ (IFNγ) enzyme-linked immunospot and intracellular cytokine flow cytometry measurements in 11 GCA and 15 PMR patients and in 26 age/sex-matched HCs. Immunoglobulin G antibodies to VZV glycoprotein (VZV-IgG) were measured in serum samples of 35 GCA and 26 PMR patients at different times of follow-up and in 58 age and sex-matched HCs by an enzyme-linked immunosorbent assay. RESULTS: The number of VZV-specific IFNγ spot-forming cells was significantly lower in GCA patients on treatment, than in age-matched HCs (p = 0.029), but was not different in PMR patients on treatment. Similar levels of VZV-IgG were found in GCA and PMR patients at baseline, compared to HCs. CONCLUSION: The finding of a decreased cell-mediated immunity to VZV, known to be of great importance in defense to the virus, indicates an increased herpes zoster risk in GCA patients compared to an already at-risk elderly population. Herpes zoster vaccination is, therefore, of special importance in GCA patients, and would ideally be administered at time of diagnosis. Interestingly, as VZV was suggested to be the trigger in GCA pathogenesis, similar levels of VZV-IgG were found in GCA patients at time of diagnosis and age-matched HCs, indicating that GCA patients did not experience herpes zoster substantially more often in the months preceding diagnosis than controls.
format Online
Article
Text
id pubmed-5661055
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-56610552017-11-08 Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis Rondaan, Christien van der Geest, Kornelis S. M. Eelsing, Elisabeth Boots, Annemieke M. H. Bos, Nicolaas A. Westra, Johanna Brouwer, Elisabeth Front Immunol Immunology INTRODUCTION: Herpes zoster, which can have a major impact on quality of life, results from reactivation of a latent varicella zoster virus (VZV) infection. We hypothesized that giant cell arteritis (GCA) patients are at increased risk of herpes zoster because of treatment with high-dose glucocorticoids and advanced age. Aim of the study, therefore, was to determine cell-mediated and humoral immunity to VZV in patients with GCA, patients with closely related disease polymyalgia rheumatica (PMR; treated with lower doses of glucocorticoids) and healthy controls (HCs). METHODS: Cell-mediated immunity to VZV was determined by performing interferon-γ (IFNγ) enzyme-linked immunospot and intracellular cytokine flow cytometry measurements in 11 GCA and 15 PMR patients and in 26 age/sex-matched HCs. Immunoglobulin G antibodies to VZV glycoprotein (VZV-IgG) were measured in serum samples of 35 GCA and 26 PMR patients at different times of follow-up and in 58 age and sex-matched HCs by an enzyme-linked immunosorbent assay. RESULTS: The number of VZV-specific IFNγ spot-forming cells was significantly lower in GCA patients on treatment, than in age-matched HCs (p = 0.029), but was not different in PMR patients on treatment. Similar levels of VZV-IgG were found in GCA and PMR patients at baseline, compared to HCs. CONCLUSION: The finding of a decreased cell-mediated immunity to VZV, known to be of great importance in defense to the virus, indicates an increased herpes zoster risk in GCA patients compared to an already at-risk elderly population. Herpes zoster vaccination is, therefore, of special importance in GCA patients, and would ideally be administered at time of diagnosis. Interestingly, as VZV was suggested to be the trigger in GCA pathogenesis, similar levels of VZV-IgG were found in GCA patients at time of diagnosis and age-matched HCs, indicating that GCA patients did not experience herpes zoster substantially more often in the months preceding diagnosis than controls. Frontiers Media S.A. 2017-10-24 /pmc/articles/PMC5661055/ /pubmed/29118757 http://dx.doi.org/10.3389/fimmu.2017.01377 Text en Copyright © 2017 Rondaan, van der Geest, Eelsing, Boots, Bos, Westra and Brouwer. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rondaan, Christien
van der Geest, Kornelis S. M.
Eelsing, Elisabeth
Boots, Annemieke M. H.
Bos, Nicolaas A.
Westra, Johanna
Brouwer, Elisabeth
Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis
title Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis
title_full Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis
title_fullStr Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis
title_full_unstemmed Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis
title_short Decreased Immunity to Varicella Zoster Virus in Giant Cell Arteritis
title_sort decreased immunity to varicella zoster virus in giant cell arteritis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661055/
https://www.ncbi.nlm.nih.gov/pubmed/29118757
http://dx.doi.org/10.3389/fimmu.2017.01377
work_keys_str_mv AT rondaanchristien decreasedimmunitytovaricellazostervirusingiantcellarteritis
AT vandergeestkornelissm decreasedimmunitytovaricellazostervirusingiantcellarteritis
AT eelsingelisabeth decreasedimmunitytovaricellazostervirusingiantcellarteritis
AT bootsannemiekemh decreasedimmunitytovaricellazostervirusingiantcellarteritis
AT bosnicolaasa decreasedimmunitytovaricellazostervirusingiantcellarteritis
AT westrajohanna decreasedimmunitytovaricellazostervirusingiantcellarteritis
AT brouwerelisabeth decreasedimmunitytovaricellazostervirusingiantcellarteritis